314 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
and commercialization of innovative medicines for patients with diabetes and other metabolic diseases. Amylin’s primary focus is on the research … , development and commercialization of a franchise of GLP-1 agonists, for the treatment of type 2 diabetes.
“Amylin’s innovative diabetes portfolio
8-K
EX-99.3
BMY
Bristol-Myers Squibb Co.
3 Jan 19
Regulation FD Disclosure
7:58am
Exhibit 99.3
Bristol-Myers Squibb to Acquire Celgene to Create a Premier
Innovative Biopharma Company
· Highly Complementary Portfolios … with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Apr 13
Departure of Directors or Certain Officers
12:00am
leader,” said Andreotti. “He and his team have become one of the most productive and innovative R&D organizations in the industry. Elliott has had … ways to discover, develop and deliver innovative medicines for patients with unmet medical needs,” said Cuss.
Dr. Cuss has a strong medical
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
23 Jan 15
Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer Effective May 5; Lamberto Andreotti to Become Chairman
12:00am
innovative medicines to patients.”
“I am honored to have the privilege to lead this great company,” Caforio said. “Lamberto has led the successful … , to deliver on the promise of our innovative portfolio and to continue to make a real difference for our patients.”
“This is an extraordinary company
425
EX-99.3
CELG
Celgene Corporation
3 Jan 19
Business combination disclosure
7:56am
Exhibit 99.3
Bristol-Myers Squibb to Acquire Celgene to Create a Premier
Innovative Biopharma Company
· Highly Complementary Portfolios … with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities
8-K
EX-99.1
js8336qilo0q8 lay
27 Feb 15
Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus
12:00am
DEFA14A
g4jo6
8 Apr 13
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
hqy0e75uqdo6zzu18y
23 Jul 18
Bristol-Myers Squibb Announces Departure of Chief Commercial Officer
4:34pm
425
ml9s4ndldfaw36tvjrxx
31 Jan 19
Business combination disclosure
12:00am
425
9yzmt8 pagmh7kpg
17 Jan 19
Business combination disclosure
12:00am
SC TO-C
EX-99.6
uuxfpy9xgefpqnlhj
5 Oct 20
Information about tender offer
5:13pm
SC TO-C
EX-99.7
7ai6e0nih
5 Oct 20
Information about tender offer
5:13pm
8-K
EX-99.1
wehx9ehi
20 Nov 19
Creating a Leading Biopharma Company
5:21pm
8-K
EX-99.1
n6j69d bt
3 Oct 12
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
12:00am
8-K
EX-99.1
hj0xa7mbb39kgfo
5 Dec 07
Other Events
12:00am
8-K
EX-99.1
jkv7h5yc2zgskd
8 Mar 10
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
p5uwspr4
12 Apr 19
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
5:27pm
425
EX-99.1
8g4f13m8n4yo821t4bo
12 Apr 19
Business combination disclosure
5:25pm
8-K
EX-99.1
uvj1lnscn 7r23
8 Jan 24
Regulation FD Disclosure
10:29am
425
pbfnqtp q8ty4ea7e5
15 Mar 19
Business combination disclosure
5:23pm